| Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1 (NCT02775292) | Jonsson Comprehensive Cancer Center | 2017-01-03 |
| Pocket Phantom Tool in Improving Accuracy of Quantitative PET/CT Imaging of Patients With Solid Tumors (NCT02822365) | University of Washington | 2016-08-24 |
| Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy (NCT02432963) | City of Hope Medical Center | 2016-06-14 |
| Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer (NCT02627430) | National Cancer Institute (NCI) | 2016-03-01 |
| Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies (NCT02116777) | National Cancer Institute (NCI) | 2014-05-16 |
| Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors (NCT01654965) | National Cancer Institute (NCI) | 2012-07-24 |
| Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery (NCT01625156) | National Cancer Institute (NCI) | 2012-05-01 |
| Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01548482) | National Cancer Institute (NCI) | 2012-03-01 |
| Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors (NCT01326702) | National Cancer Institute (NCI) | 2011-07-01 |
| Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery (NCT01375829) | National Cancer Institute (NCI) | 2011-06-27 |
| High-Dose or Low-Dose Vorinostat in Combination With Carboplatin or Paclitaxel in Treating Patients With Advanced Solid Tumors (NCT01281176) | National Cancer Institute (NCI) | 2011-02-09 |
| MK2206 and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Metastatic Breast Cancer (NCT01263145) | National Cancer Institute (NCI) | 2011-01-05 |
| Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors (NCT01281150) | National Cancer Institute (NCI) | 2011-01-01 |
| Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer (NCT01264432) | National Cancer Institute (NCI) | 2011-01-01 |
| Weekly Doses of Cilengitide and Paclitaxel in Treating Patients With Advanced Solid Tumors That Cannot Be Removed by Surgery (NCT01276496) | National Cancer Institute (NCI) | 2010-12-01 |
| RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer (NCT01217411) | National Cancer Institute (NCI) | 2010-10-01 |
| Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors (NCT01218620) | National Cancer Institute (NCI) | 2010-09-01 |
| ABT-888 and Gemcitabine Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT01154426) | National Cancer Institute (NCI) | 2010-05-01 |
| Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors (NCT01131234) | National Cancer Institute (NCI) | 2010-05-01 |
| Cilengitide and Sunitinib Malate in Treating Patients With Advanced Solid Tumors or Glioblastoma Multiforme (NCT01122888) | National Cancer Institute (NCI) | 2009-12-01 |
| Azacitidine and Oxaliplatin In Treating Patients With Advanced Cancers Relapsed or Refractory to Any Platinum Therapy (NCT01039155) | National Cancer Institute (NCI) | 2009-12-01 |
| Selumetinib and Cixutumumab in Treating Patients With Advanced Solid Malignancies (NCT01061749) | National Cancer Institute (NCI) | 2009-11-01 |
| Selumetinib in Cancers With BRAF Mutations (NCT00888134) | National Cancer Institute (NCI) | 2009-07-01 |
| GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery (NCT00878163) | National Cancer Institute (NCI) | 2009-03-31 |
| Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery (NCT00608361) | National Cancer Institute (NCI) | 2008-10-01 |
| Veliparib, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Cancer (NCT00535119) | National Cancer Institute (NCI) | 2007-09-01 |
| Sunitinib Malate in Treating Patients With Unresectable or Metastatic Kidney Cancer or Other Advanced Solid Tumors (NCT00499135) | National Cancer Institute (NCI) | 2007-05-22 |
| Eribulin Mesylate and Gemcitabine Hydrochloride in Treating Patients With Metastatic Solid Tumors or Solid Tumors That Cannot be Removed by Surgery (NCT00410553) | National Cancer Institute (NCI) | 2006-11-14 |
| Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by Surgery (NCT00334789) | National Cancer Institute (NCI) | 2006-06-12 |
| Vaccine Therapy, GM-CSF, and Interferon Alfa-2b in Treating Patients With Locally Advanced or Metastatic Cancer That Expresses Carcinoembryonic Antigen (CEA) (NCT00217373) | National Cancer Institute (NCI) | 2005-06-01 |
| Neoadjuvant Tipifarnib, Docetaxel, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIA or Stage IIIB Breast Cancer (NCT00070252) | National Cancer Institute (NCI) | 2003-09-01 |
| Erlotinib Hydrochloride and Irinotecan Hydrochloride in Treating Patients With Advanced Solid Tumors (NCT00045201) | National Cancer Institute (NCI) | 2002-06-13 |